Advertisement Pharmaceutical Business review - Page 456 of 5289 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
September 10, 2026

Solstice Oncology secures $225m to drive porustobart’s development for cancer

Harbour BioMed’s partner Solstice Oncology has raised $225m in funding to advance its lead candidate, porustobart, a neoadjuvant immuno-oncology therapy.

Continue
Porustobart is a second-generation, Fc-enhanced CTLA-4 antibody developed by Harbour BioMed. Credit: T. Schneider / Shutterstock.com.
September 10, 2026

TwoStep Therapeutics secures $62.5m funding to advance TS-104

TwoStep’s approach uses a PIP that is designed to bind five tumour-associated integrins present in various solid tumours. Credit: angellodeco / Shutterstock.com.
September 9, 2026

FDA grants RMAT designation to RiboX’s RXRG001 for xerostomia

RXRG001 is a proprietary circular RNA therapy encoding human aquaporin-1, a protein involved in fluid transport. Credit: Krisana Antharith / Shutterstock.com.

Contracts

January 23, 2025

Kamada to supply immune globulin products in Latin America

KAMRAB must be administered alongside a complete rabies vaccine regimen. Credit: Nappy on Unsplash.

Bavarian Nordic secures $156.8m US vaccine deal

Boehringer Ingelheim receives EC conditional marketing approval for spesolimab

Marinus Pharmaceuticals signs collaboration agreement with Tenacia Biotechnology

Deals

Deals January 20, 2025

Fermion and Simcere to partner on development of pain treatment drug

Pharmaceutical Business Review

WuXi Biologics and Sino Biopharm collaborate on monoclonal antibody discovery

Merck enhances ophthalmology portfolio with EyeBio acquisition

Biocon signs licensing and supply deal for diabetes drug in Brazil

Popular

  1. Gilead launches research facility in US for new medicine development
  2. LSTM opens $23m robotic AI lab for infection research
  3. Novartis India acquires Pfizer brands for $132m
  4. AtomVie opens $160m radiopharmaceutical manufacturing facility in Ontario
  5. FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer

PRESS RELEASES

Gerresheimer Reports Slight Revenue Growth in Q1 2026 and a Strong Focus on Free Cash Flow
Gerresheimer Reports Slight Revenue Growth in Q1 2026 and a Strong Focus on Free Cash Flow
Uwe Röhrhoff Steps Down as Interim CEO of Gerresheimer AG
Uwe Röhrhoff Steps Down as Interim CEO of Gerresheimer AG
SCHOTT Pharma Expands Portfolio for Sensitive Biologics with cartriQ® BioPure
SCHOTT Pharma Expands Portfolio for Sensitive Biologics with cartriQ® BioPure
Pharmaceutical Business Review
SCHOTT Pharma and Nemera Deliver Verified Pen Injector Platform with Sterile Cartridge System
SCHOTT Pharma Invests in Sterile Cartridge Production in Hungary
SCHOTT Pharma Invests in Sterile Cartridge Production in Hungary

Suppliers

Whitepapers

Smoothly Through the Production Process: EVERIC™ Strong/Smooth Test
Smoothly Through the Production Process: EVERIC™ Strong/Smooth Test
Strengths and Weaknesses of Different Prefilled Syringes for Injections in Hospitals: A Case Study by Niklas Niederwieser and Patrick Gallagher SCHOTT AG
Strengths and Weaknesses of Different Prefilled Syringes for Injections in Hospitals: A Case Study by Niklas Niederwieser and Patrick Gallagher SCHOTT AG
Tracking the Cracking: How to Optimise Pharma Fill-and-Finish Processes by Use of Strength Testing and Fractography
Tracking the Cracking: How to Optimise Pharma Fill-and-Finish Processes by Use of Strength Testing and Fractography